- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
ATA Annual Meeting | Conferences
Cabozantinib Continues to Improve PFS, Regardless of Duration of Previous Lenvatinib Therapy in RAI-Refractory DTC
October 24, 2022
An extended follow-up of the phase 3 COSMIC-311 trial supported the use of cabozantinib to treat patients with radioiodine-refractory differentiated thyroid cancer, irrespective of the duration of prior lenvatinib received.
Psychiatric History May Prompt Patients’ Decisions for Faster Surgical Treatment in Thyroid Cancer
October 22, 2022
Psychiatric history may be an important factor for physicians to consider when counseling patients on their treatment options with thyroid cancer, according to a retrospective chart review.
Study Reassures Transition From Specialist to PCP After Thyroid Cancer Treatment
October 22, 2022
After participating in a primary care-based follow-up program, 53% of patients have been discharged and have fully transitioned to their primary care provider.
Higher BMI May Induce More Aggressive Disease, Worse Clinical Outcomes in Differentiated Thyroid Carcinoma
October 21, 2022
Investigators found that higher body mass index is associated with more aggressive differentiated thyroid carcinoma tumors, as well as an increased risk for worse clinical outcomes, with patients with a BMI above 28.4 being at a higher risk.
Chanock Discusses the Impact of the Chernobyl Accident on Thyroid Cancer
October 21, 2022
Stephen J. Chanock, MD, discusses the background of the Chernobyl accident and its association with thyroid cancer.
Real-World Retrospective Review Confirms Efficacy of Frontline Lenvatinib Monotherapy in RAI-Refractory DTC
October 21, 2022
A real-world retrospective patient chart review showed a 72.4% physician-reported best overall response, confirming the agent’s clinical efficacy to treat patients with RAI-refractory differentiated thyroid cancer.
Cancer Survivors May Be at Increased Risk for Secondary Primary Thyroid Cancer
October 21, 2022
A study found that after their first primary malignancy diagnosis, cancer survivors are at a significantly increased risk for secondary primary thyroid cancer, with other half of cases occurring in the first 3 years.
Significant Increase in Peripheral NK Cells May Support Lenvatinib Efficacy in Advanced Thyroid Cancer
October 21, 2022
A prospective study of blood samples confirmed the immune-modulatory effect of lenvatinib with a significant increase in the peripheral natural killer cells among patients with advanced thyroid cancer.
Withholding RAI Therapy in Low-Risk Pediatric DTC Continues to Yield Comparable Remission Rates
October 20, 2022
Following American Thyroid Association guidelines, a retrospective study confirmed that remission rates were comparable in pediatric patients with low-risk differentiated thyroid carcinoma who did and did not receive radioactive iodine therapy.
Further Research Needed to Evaluate Peds vs Adults With Thyroid Cancer
October 20, 2022
Aime T. Franco, PhD, provides an overview of her discussion regarding the molecular landscape of pediatric patients with thyroid cancer at the 91st Annual Meeting of the American Thyroid Association.